Daniel Wolff

Summary

Affiliation: University of Regensburg
Country: Germany

Publications

  1. doi request reprint Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease
    Daniel Wolff
    Department of Hematology and Clinical Oncology, University of Regensburg, Germany
    Biol Blood Marrow Transplant 17:1-17. 2011
  2. pmc The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland
    Daniel Wolff
    Abteilung für Hämatologie und Internistische Onkologie, Universitat Regensburg, Franz Josef Strauss Allee 11, 93053 Regensburg, Germany
    Dtsch Arztebl Int 108:732-40. 2011
  3. doi request reprint Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD
    Daniel Wolff
    Department of Hematology and Clinical Oncology, University of Regensburg, F J Strauss Allee 11, Regensburg, Germany
    Biol Blood Marrow Transplant 16:1611-28. 2010
  4. ncbi request reprint Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease
    D Wolff
    Department of Hematology and Oncology, University of Regensburg, Regensburg, Germany
    Curr Pharm Des 15:1974-97. 2009
  5. doi request reprint Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers
    Daniel Wolff
    Department of Hematology and Clinical Oncology, University of Regensburg, Germany
    Biol Blood Marrow Transplant 19:767-76. 2013
  6. ncbi request reprint Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation
    Gerhard C Hildebrandt
    Department of Hematology and Oncology, University of Regensburg Medical School, Regensburg, Germany
    Biol Blood Marrow Transplant 14:67-74. 2008
  7. doi request reprint Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD
    Johannes K H Meier
    Department of Cranio Maxillo Facial Surgery, University of Regensburg, Regensburg, Germany
    Clin Oral Investig 15:127-39. 2011
  8. doi request reprint Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease
    Oliver Grauer
    Department of Neurology, University Medical Centre Regensburg, Universitätsstraße 84, Regensburg, Germany
    Brain 133:2852-65. 2010
  9. doi request reprint Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease
    Anke Heidewig Hautmann
    Department of Hematology and Oncology, University of Regensburg, F J Strauss Allee 11, Regensburg, Germany
    Transpl Int 24:867-79. 2011
  10. doi request reprint Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD
    Tina Dietrich-Ntoukas
    Department of Ophthalmology, University Medical Center, Regensburg, Regensburg, Germany
    Cornea 31:299-310. 2012

Collaborators

Detail Information

Publications22

  1. doi request reprint Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease
    Daniel Wolff
    Department of Hematology and Clinical Oncology, University of Regensburg, Germany
    Biol Blood Marrow Transplant 17:1-17. 2011
    ..Moreover, the sparse evidence for most treatment entities indicates the urgent need for systematic evaluation of second-line treatment options in cGVHD...
  2. pmc The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland
    Daniel Wolff
    Abteilung für Hämatologie und Internistische Onkologie, Universitat Regensburg, Franz Josef Strauss Allee 11, 93053 Regensburg, Germany
    Dtsch Arztebl Int 108:732-40. 2011
    ..cGVHD is a chronic multisystem disease due to impaired tolerance mechanisms. It affects many organs in variable ways, impairing organ function and lowering quality of life...
  3. doi request reprint Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD
    Daniel Wolff
    Department of Hematology and Clinical Oncology, University of Regensburg, F J Strauss Allee 11, Regensburg, Germany
    Biol Blood Marrow Transplant 16:1611-28. 2010
    ..Beside systemic immunosuppression, the use of topical immunosuppressive interventions may improve local response rates and may be used as the only treatment in mild localized organ manifestations of cGVHD...
  4. ncbi request reprint Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease
    D Wolff
    Department of Hematology and Oncology, University of Regensburg, Regensburg, Germany
    Curr Pharm Des 15:1974-97. 2009
    ..Moreover, successful topical treatment of manifestations of chronic GVHD manifestations has been reported consisting of topical steroids like budesonide, topical calcineurin inhibitors, or PUVA...
  5. doi request reprint Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers
    Daniel Wolff
    Department of Hematology and Clinical Oncology, University of Regensburg, Germany
    Biol Blood Marrow Transplant 19:767-76. 2013
    ..Our survey also demonstrates that clinicians chose salvage therapies for steroid-refractory aGVHD based on their centers' own clinical experience...
  6. ncbi request reprint Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation
    Gerhard C Hildebrandt
    Department of Hematology and Oncology, University of Regensburg Medical School, Regensburg, Germany
    Biol Blood Marrow Transplant 14:67-74. 2008
    ..2% (P = .04). Multivariate analysis proved recipient but not donor NOD2/CARD15 variants to be a novel independent risk factor for BO development, and NOD2/CARD15 typing may help identify patients at increased risk for BO...
  7. doi request reprint Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD
    Johannes K H Meier
    Department of Cranio Maxillo Facial Surgery, University of Regensburg, Regensburg, Germany
    Clin Oral Investig 15:127-39. 2011
    ....
  8. doi request reprint Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease
    Oliver Grauer
    Department of Neurology, University Medical Centre Regensburg, Universitätsstraße 84, Regensburg, Germany
    Brain 133:2852-65. 2010
    ....
  9. doi request reprint Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease
    Anke Heidewig Hautmann
    Department of Hematology and Oncology, University of Regensburg, F J Strauss Allee 11, Regensburg, Germany
    Transpl Int 24:867-79. 2011
    ..In this report, we provide recommendations for metabolic bone diseases agreed upon by the working party. This includes guidelines for diagnosis, prevention, and therapeutic options in patients with low bone mass or AVN...
  10. doi request reprint Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD
    Tina Dietrich-Ntoukas
    Department of Ophthalmology, University Medical Center, Regensburg, Regensburg, Germany
    Cornea 31:299-310. 2012
    ..Ocular chronic graft-versus-host disease (cGVHD) is one of the most frequent long-term complications after hematopoietic stem cell transplantation and is often associated with significant morbidity and reduced quality of life...
  11. ncbi request reprint Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination
    Ernst Holler
    Department of Haematology Oncology, Medical Centre, University of Regensburg, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
    Blood 107:4189-93. 2006
    ..Our data further support an interaction between gastrointestinal defense mechanisms, activation of the innate immune system, and specific transplant-related complications...
  12. pmc Muscle cramps and neuropathies in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease
    Peter D Kraus
    Department of Neurology, University Medical Centre Regensburg, Regensburg, Germany
    PLoS ONE 7:e44922. 2012
    ..Peripheral nervous system manifestations of GVHD are rare but often disabling. Whereas immune-mediated neuropathies are an established feature of GVHD, muscle cramps are not well characterized...
  13. doi request reprint G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation
    Ya Yi Chang
    Department of Hematology and Oncology, University of Regensburg Medical Center, Regensburg, Germany
    Cytokine 48:218-25. 2009
    ....
  14. ncbi request reprint Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning
    Karin Landfried
    Department of Hematology Oncology, University Medical Centre, University of Regensburg, Regensburg, Germany
    Curr Opin Oncol 21:S39-41. 2009
    ..To improve long-term outcome in GvHD, pre-emptive strategies or more selective approaches aimed at immunomodulation rather than immunosuppression are needed...
  15. doi request reprint The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation
    E Holler
    Department of Haematology Oncology, University of Regensburg, Regensburg, Germany
    Int J Immunogenet 35:381-4. 2008
    ..Thus our observation indicates that the presence of a defect in innate immunity signalling in donor monocytes and possibly antigen presenting cells is most prominent in patients having additional T cell deficiency...
  16. doi request reprint Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase
    Karin Landfried
    Department of Haematology Oncology, University Medical Center, Regensburg, Germany
    Blood 118:6971-4. 2011
    ..GVHD-dependent induction of IDO was further suggested by increased expression of IDO mRNA in intestinal biopsies from patients with severe GVHD. Our data indicate reactive release of kynurenines in GVHD-associated inflammation...
  17. doi request reprint Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats
    Vicky Sender
    Department of Hematology and Oncology, Department of Medicine, University of Rostock, Rostock, Germany
    Immunopharmacol Immunotoxicol 31:595-600. 2009
    ..Gastrointestinal toxicity is the dose-limiting factor in the treatment with Treo and TBI. Furthermore, Treo possesses certain characteristics of a radiosensitizer...
  18. doi request reprint The lack of memory B cells including T cell independent IgM+ IgD+ memory B cells in chronic graft-versus host disease is associated with susceptibility to infection
    Inken Hilgendorf
    Department of Hematology, Oncology, Palliative Care, University of Rostock, Rostock, Germany
    Transpl Int 25:87-96. 2012
    ..Our data underline the close association of diminished B cell counts with cGVHD and the onset of severe infections. The lack of IgM(+) memory B cells in patients with cGVHD may indicate functional asplenia...
  19. pmc Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease
    K Landfried
    Department of Haematology Oncology, University Medical Centre, Regensburg, Germany
    Clin Exp Immunol 159:87-92. 2010
    ..Our results suggest a loss of protective CD4 T cells in intestinal GVHD which is enhanced further by the presence of NOD2/CARD15 variants. Our study might help to identify more selective therapeutic strategies in the future...
  20. doi request reprint Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD
    H Andree
    Department of Hematology and Oncology, University of Rostock, Rostock, Germany
    Bone Marrow Transplant 42:541-6. 2008
    ..BUD represents a treatment option in mild-to-moderate cGVHD, which is well tolerated and associated with a high response rate in gastrointestinal cGVHD...
  21. doi request reprint Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution
    Abdellatif Bouazzaoui
    Department of Hematology and Oncology, University of Regensburg Medical School, Regensburg, Germany and
    Immunopharmacol Immunotoxicol 36:158-64. 2014
    ..We evaluated the impact of the conditioning regimen on aGVHD comparing Treosulfan (Treo) and Busulfan (Bu) with total body irradiation (TBI)...
  22. ncbi request reprint Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation
    Jochen Casper
    Department of Hematology and Oncology, University of Rostock, PO Box 100888, 18055 Rostock, Germany
    Blood 103:725-31. 2004
    ..4-33.4 months). In summary, the combination of treosulfan and fludarabine is a safe and efficient conditioning regimen...